**Name of Journal: *World Journal of Clinical Oncology***

**Manuscript NO: 38246**

**Manuscript Type: Original Article**

**Letter to Editor**

Dear Fang-Fang Ji,

Please find the revised manuscript taking into account the editor’s comments, asking for rewriting the “Endpoint” section due to similar sentences with other articles. In fact, similar sentences correspond to classical endpoints definitions. No specific other articles were cited.

Of note, prior reviewer’s comments were previously answered.

In order to decrease similar words/sentences with other articles, please find below the list of modifications.

Sincerely,

Dr Benoist Chibaudel

***Liste of modifications***

***Title***

**FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer**

***Introduction***

Based on the VELOUR study results and non-randomized FOLFIRI3 studies, we retrospectively analyzed. The safety and efficacy of the FOLFIRI3-aflibercept combination as second or later-line therapy in patients with mCRC.

***Endpoints***

The best ORR was defined as the best response recorded from the start of treatment until progressive disease (PD). Disease control rate (DCR) was the sum of ORR and stable disease (SD). PFS was defined as the time from the date of starting treatment to the date of progression or death (from any cause). OS was defined as the time from the date of starting treatment to the date of patient death (from any cause) or to the last date the patient was known to be alive. Toxicity was evaluated according to the United States National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03.